

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|---------------------------------------|----|---|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | IU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|---|-----------------------------|--|--|
| (51) International Patent Classification 6 : | A1 | (11) International Publication Number: | WO 98/35685 |
| A61K 31/70 // (A61K 31/70, 31:445) | | (43) International Publication Date: | 20 August 1998 (20.08.98) |
| (21) International Application Number: | PCT/US98/03004 | (81) Designated States: | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). |
| (22) International Filing Date: | 12 February 1998 (12.02.98) | (30) Priority Data: | 60/041,221 14 February 1997 (14.02.97) US |
| (71) Applicant (for all designated States except US): G.D. SEARLE AND CO. [US/US]; P.O. Box 5110, Chicago, IL 60680 (US). | | (72) Inventors; and | |
| (75) Inventors/Applicants (for US only): JACOB, Gary, S. [US/US]; G.D. Searle and Co., P.O. Box 5110, Chicago, IL 60680 (US). BLOCK, Timothy, M. [US/US]; 124 Township Line Road, Jenkintown, PA 19046 (US). DWEK, Raymond, A. [GB/GB]; Ambleside, Vernon Avenue, North Hinksey, Oxford OX2 9AU (GB). | | (74) Agents: COHEN, Charles, E. et al.; Senniger, Powers, Leavitt & Roedel, 16th floor, One Metropolitan Square, St. Louis, MO 63102 (US). | |

(54) Title: USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS

(57) Abstract

Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antivirals agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immunostimulating agents.



Richard A. Mueller et al.
Serial No. 09/249,220
Filed 2/12/99
Our File SRL 6109
Ref. No. 52

USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL
COMPOUNDS IN COMBINATION THERAPY FOR TREATING
HEPATITIS VIRUS INFECTIONS

BACKGROUND OF THE INVENTION

5 Field of the Invention

The present invention relates to methods and compositions for treating hepatitis virus infections, especially hepatitis B virus infections, in mammals, especially humans. The methods comprise (1) administering 10 *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/-immunostimulating agents, or (2) administering 15 *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immunostimulating agents. Such combinations of anti-hepatitis viral agents show unexpected efficacy in inhibiting replication and 20 secretion of hepatitis viruses in cells of mammals infected with these viruses.

Description of Related Art

Hepatitis Viruses

Hepatitis B Virus (HBV, HepB) is a causative agent of acute and chronic liver disease including liver fibrosis, cirrhosis, inflammatory liver disease, and hepatic cancer that can lead to death in some patients (Joklik, Wolfgang K., *Virology*, Third Edition, Appleton & Lange, Norwalk, Connecticut, 1988 (ISBN 0-8385-9462-X)). Although 25 effective vaccines are available, there are still more than 300 million people worldwide, i.e., 5% of the world's population, chronically infected with the virus 30

(Locarnini, S. A., et. al., *Antiviral Chemistry & Chemotherapy* (1996) 7(2):53-64). Such vaccines have no therapeutic value for those already infected with the virus. In Europe and North America, between 0.1% to 1% of the population is infected. Estimates are that 15% to 20% of individuals who acquire the infection develop cirrhosis or another chronic disability from HBV infection. Once liver cirrhosis is established, morbidity and mortality are substantial, with about a 5-year patient survival period (Blume, H., E., et.al., *Advanced Drug Delivery Reviews* (1995) 17:321-331). It is therefore necessary and of high priority to find improved and effective anti-HBV anti-hepatitis therapies (Locarnini, S. A., et. al., *Antiviral Chemistry & Chemotherapy* (1996) 7(2): 53-64).

Other hepatitis viruses significant as agents of human disease include Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis Delta, Hepatitis E, Hepatitis F, and Hepatitis G (Coates, J. A. V., et.al., *Exp. Opin. Ther. Patents* (1995) 5(8):747-756). In addition, there are animal hepatitis viruses that are species-specific. These include, for example, those infecting ducks, woodchucks, and mice.

1,5-dideoxy-1,5-imino-D-glucitol Compounds

1,5-dideoxy-1,5-imino-D-glucitol (also known as 1-deoxynojirimycin, DNJ) and its N-alkyl derivatives are known inhibitors of the N-linked oligosaccharide processing enzymes alpha glucosidase I and II (Saunier et al., *J. Biol.Chem.* (1982) 257:14155-14161 (1982); Elbein, *Ann. Rev. Biochem.* (1987) 56:497-534). As glucose analogs, they also have potential to inhibit glucose transport, glucosyl-transferases, and/or glycolipid synthesis (Newbrun et al., *Arch. Oral Biol.* (1983) 28: 516-536; Wang et al., *Tetrahedron Lett.* (1993) 34:403-406). Their inhibitory activity against glucosidases has led to the development of these compounds as anti-

hyperglycemic agents and antiviral agents. See, for example, PCT International Publication WO 87/03903 and U.S. Patents 4,065,562; 4,182,767; 4,533,668; 4,639,436; 4,849,430; 4,957,926; 5,011,829; and 5,030,638.

Glucosidase inhibitors such as *N*-alkyl-1,5-dideoxy-1,5-imino-D-glucitol compounds wherein the alkyl group contains between three and six carbon atoms have been shown to be effective in the treatment of Hepatitis B infection (PCT International Publication WO 95/19172). For example, *n*-butyl-deoxynojirimycin (*n*-butyl-DNJ; *N*-butyl-1-5-dideoxy-1,5-imino-D-glucitol) is effective for this purpose (Block, T. M., *Proc. Natl. Acad. Sci. USA* (1994) 91:2235-2239; Ganem, B. *Chemtracts: Organic Chemistry* (1994) 7(2), 106-107). *N*-butyl-DNJ has also been tested as an anti-HIV-1 agent in HIV infected patients, and is known to be well tolerated. Another alpha glucosidase inhibitor, deoxynojirimycin (DNJ), has been suggested as an antiviral agent for use in combination with *N*-(phosphonoacetyl)-L-aspartic acid (PALA) (WO 93/18763). However, combinations of *N*-substituted-imino-D-glucitol derivatives and other antiviral agents for the treatment of hepatitis virus infections have not been previously disclosed or suggested.

Nucleoside and Nucleotide Antiviral Agents

Reverse transcriptase inhibitors, including the class of nucleoside and nucleotide analogs, were first developed as drugs for the treatment of retroviruses such as human immunodeficiency virus (HIV), the causative agent of AIDS. Increasingly, these compounds have found use against other viruses, including both RNA and DNA viruses, via viral screening and chemical modification strategies. Nucleoside and nucleotide analogs exert their antiviral activities by inhibiting the corresponding DNA and RNA polymerases responsible for synthesis of viral DNA and

RNA, respectively. Because viruses contain different forms of polymerases, the same nucleoside/nucleotide compound can have a dramatically different effect against different viruses. For example, lamivudine (3TC™) appears to be useful against HBV infection, whereas zidovudine (AZT™) appears to have little use against the same virus (Gish, R.G., et al., *Exp. Opin. Invest. Drugs* (1995) 4(2):95-115).

Toxicity has been significant with some nucleoside analog antivirals. For example, clinical tests on the use of the nucleoside analog fialuridine (FIAU) for treatment of chronic hepatitis B were suspended recently due to drug-related liver failure leading to death in some patients. Consequently, there is still a need for safer drug regimens for the treatment of hepatitis B infections and hepatitis (Mutchnick, M. G., et. al., *Antiviral Research* (1994) 24:245-257).

Immunomodulators and Immunostimulants

Immunomodulators/immunostimulators such as interferon alfa and other cytokines have been used for the treatment of HBV infection with promising results. Unfortunately, the response rates are lower than desired. Interferon treatment is currently approved by the FDA for the treatment of Hepatitis B. Other immune system-affecting drug candidates are presently being investigated. These include thymic pepides for use in the treatment of chronic hepatitis B (CHB), isoprinosine, steroids, Shiff base-forming salicylaldehyde derivatives such as Tucaresol, levamisol, and the like (Gish, R. G., et.al., *Exp. Opin. Invest. Drugs* (1995) 4(2):95-115; Coates, J.A.V., et.al., *Exp. Opin. Ther. Patents* (1995) 5(8):747-765).

The use of *N*-substituted-imino-D-glucitol compounds in combination with immunomodulating/immunostimulating agents is novel.

SUMMARY OF THE INVENTION


As noted above, the combination of *N*-substituted-imino-D-glucitol compounds and derivatives thereof with other anti-hepatitis virus compounds has, to the present 5 inventor's knowledge, neither been suggested nor disclosed. The use of two or more anti-viral agents to provide improved therapy for the treatment of hepatitis B virus infections is desirable due to the morbidity and mortality of the disease. Combination therapy is also 10 desirable since it should reduce toxicity in patients as it enables the physician to administer lower doses of one or more of the drugs being given to a patient.

Combination therapy can also help to prevent the development of drug resistance in patients (Wiltink, E. H. 15 H., *Pharmaceutisch Weekblads Scientific Edition* (1992) 14(4A):268-274). The result of an improved efficacy configuration combined with a relative lack of toxicity and development of resistance would provide a much improved drug treatment profile.

The present inventor has surprisingly discovered that 20 the combined use of *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds and nucleoside or nucleotide antiviral compounds, or combinations thereof, and/or immunomodulators/immunostimulants, results in unexpectedly 25 greater anti-hepatitis virus effectiveness of the compounds compared to the combined antiviral activities expected of the individual compounds alone. Whether this is due to different mechanisms of action of the different classes of drugs employed or some other biological 30 phenomenon is presently unclear.

Accordingly, in a first aspect, the present invention provides a method of treating a hepatitis virus infection in a mammal, comprising administering to said mammal a first amount of an *N*-substituted-1,5-dideoxy-1,5-imino-D- 35 glucitol compound of Formula I:

6



I

wherein:

R is selected from the group consisting of arylalkyl,
5 cycloalkylalkyl, and branched or straight chain alkyl
having a chain length of C₁ to C₂₀, and

W, X, Y, and Z are each independently selected from
the group consisting of hydrogen, alkanoyl, aroyl, and
trifluoroalkanoyl; and

10 a second amount of an antiviral compound selected
from the group consisting of a nucleoside antiviral
compound, a nucleotide antiviral compound, and mixtures
thereof,

15 wherein said first and second amounts of said
compounds together comprise an anti-hepatitis virus
effective amount of said compounds.

In a second aspect, the present invention provides a
method of treating a hepatitis B virus infection in a
mammal, comprising administering to said mammal from about
20 0.1 mg/kg/day to about 100 mg/kg/day of an N-substituted-
1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I, as
above, and from about 0.1 mg/person/day to about 500
mg/person/day of a compound selected from the group
consisting of a nucleoside antiviral compound, a
nucleotide antiviral, and mixtures thereof.

The present invention also provides a method of
treating a hepatitis B virus infection in a human patient,
comprising administering to said human patient from about

0.1 mg/kg/day to about 100 mg/kg/day of *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol and from about 0.1 mg/person/day to about 500 mg/person/day of (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate.

5 Also provided is a composition, comprising an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I, as above, and an antiviral compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral compound, and mixtures thereof.

10 The invention also provides a pharmaceutical composition, comprising a first amount of an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I, as above, and a second amount of an antiviral compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral compound, and mixtures thereof, as well as a pharmaceutically acceptable carrier, diluent, or excipient.

15 The invention further provides a pharmaceutical composition for treating a hepatitis B virus infection in a mammal, comprising from about 0.1 mg to about 100 mg of an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I, as above, and from about 0.1 mg to about 500 mg of a compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral, and mixtures thereof.

20 Also provided is a pharmaceutical composition for treating a hepatitis B virus infection in a human patient, comprising from about 0.1 mg to about 100 mg of *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, and from about 0.1 mg to about 500 mg of (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate.

25 In addition to the foregoing, the present invention also provides methods and compositions like those listed above, wherein the *N*-substituted-1,5-dideoxy-1,5-imino-D-

5 glucitol compounds of Formula I, nucleoside antiviral compounds, nucleotide antiviral compounds, or mixtures of nucleoside and nucleotide antiviral compounds, are used in combination with immunomodulators, immunostimulators, or mixtures of immunomodulators and immunostimulators.

In another aspect, the present invention also provides methods and compositions like those listed before the paragraph immediately above, wherein the *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds of
10 Formula I are used in combination with immunomodulators, immunostimulators, or mixtures of immunomodulators and immunostimulators, but without nucleoside antiviral compounds, nucleotide antiviral compounds, or mixtures of nucleoside and nucleotide antiviral compounds.

15 Further scope of the applicability of the present invention will become apparent from the detailed description and drawings provided below. However, it should be understood that the following detailed description and examples, while indicating preferred
20 embodiments of the invention, are given by way of illustration only since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

25

BRIEF DESCRIPTION OF THE DRAWINGS

The above and other objects, features, and advantages of the present invention will be better understood from the following detailed description taken in conjunction with the accompanying drawings, all of
30 which are given by way of illustration only, and are not limitative of the present invention, in which:

Figure 1 shows the anti-hepatitis B virus activity of (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC) alone and in combination with *N*-nonyl-DNJ *in vitro*.

Figure 2 shows the plasma concentration of *N*-nonyl-DNJ versus dose of *N*-nonyl-DNJ for each animal in Example 4, from samples taken during dosing. Animals are indicated by unique letters, and a small amount of random noise has been added to the dose value so that overlapping values can be distinguished.

Figure 3 shows the slope of Log(IPDNA + 10) to week versus dose. A distinct letter is used for each animal. The fitted line is from a four parameter logistic model. The parameters of the fitted curve and their approximate standard errors are shown on the plot.

DETAILED DESCRIPTION OF THE INVENTION

The following detailed description is provided to aid those skilled in the art in practicing the present invention. Even so, this detailed description should not be construed to unduly limit the present invention as modifications and variations in the embodiments discussed herein can be made by those of ordinary skill in the art without departing from the spirit or scope of the present inventive discovery.

The contents of each of the references cited herein, including the contents of the references cited within these primary references, are herein incorporated by reference in their entirety.

The present inventor has discovered that combinations of *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds with anti-hepatitis virus nucleoside or nucleotide analogs, and/or immunomodulators/-immunostimulants, are more effective in inhibiting hepatitis virus replication than that which would be expected via the combined use of the individual compounds.

The present invention thus provides pharmaceutical compositions and methods of treating hepatitis virus infections, especially hepatitis B virus infections, in humans, other mammals, and cells using a combination of an


N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound with either an antiviral nucleoside, an antiviral nucleotide, mixtures thereof, and/or an immunomodulating or immunostimulating agent. The *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds have basic nitrogen atoms and may be used in the form of a pharmaceutically acceptable salt. Nucleosides and nucleotides useful in the present invention are substituted purine or pyrimidine heterocycles further substituted with R¹ at the 9 position in the case of purines or with R¹ at the 1 position in the case of pyrimidines. The immunomodulating and immunostimulating agents useful in the present invention include those that stimulate immune responses effective in controlling or eliminating viruses or other infectious agents. Non-limiting examples of such immunomodulating and immunostimulating agents include cytokines, peptide agonists, steroids, and classic drugs such as levamisol. The drug combinations of this invention may be provided to a cell or cells, or to a human or other mammalian patient, either in separate pharmaceutically acceptable formulations, formulations containing more than one therapeutic agent, or by an assortment of single agent and multiple agent formulations. However administered, these drug combinations form an anti-hepatitis virus effective amount of components.

As used herein, the term "anti-hepatitis-virus effective amount" refers to a combined amount of (1) an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound with either an antiviral nucleoside, an antiviral nucleotide, a mixture of an antiviral nucleoside and an antiviral nucleotide, or an immunomodulating/-immunostimulating agent (or mixtures thereof), or (2) a combined amount of an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound with an antiviral nucleoside, an antiviral nucleotide, or a mixture thereof, and an immunomodulating/-immunostimulating agent (or mixtures

thereof) effective in treating hepatitis virus infection. The antiviral effectiveness of the aforementioned combinations may involve a variety of different phenomena associated with viral replication and assembly. These may 5 include, for example, blocking hepatitis viral DNA synthesis; blocking viral transcription; blocking virion assembly; blocking virion release or secretion from infected cells; blocking or altering viral protein function, including the function of viral envelope 10 protein(s); and/or the production of immature or otherwise non-functional virions. The overall effect is an inhibition of viral replication and infection of additional cells, and therefore inhibition of the progress of infection in the patient.

15 **N-substituted-1,5-dideoxy-1,5-imino-D-glucose Compounds**

N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds useful in the present invention are represented by structure I below:



20

I

wherein R is selected from arylalkyl, cycloalkylalkyl, and branched or straight chain alkyl having a chain length of C₁ to C₂₀, preferably C₂ to C₁₄, more preferably C₆ to C₁₂. R can also be C₁ to C₂₀ alkyl, preferably C₂ to C₁₄, more 25 preferably C₆ to C₁₂, containing 1 to 5, more preferably 1 to 3, most preferably 1 to 2, oxygen atoms, i.e., oxa derivatives. Preferred R oxa derivatives are 3-oxanonyl, 3-oxadecyl, 7-oxanonyl, and 7-oxadecyl. W, X, Y and Z are

independently selected from hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl.

Representative *N*-substituted-imino-D-glucitol compounds useful in the present invention include, but are 5 not limited to:

N-(n-hexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol,
10 tetrabutyrate;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
15 *N*-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
20 *N*-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
25 *N*-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
30 *N*-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
35 *N*-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol,
5 tetrabutyrate;
N-(n-decyl-)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(n-undecyl-)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
10 *N*-(n-dodecyl-)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
15 tetrabutyrate;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
20 *N*-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(7-methyloctyl-)-1,5-dideoxy-1,5-imino-D-glucitol,
25 tetrabutyrate;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
30 *N*-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
35 tetrabutyrate;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol,

tetrabutyrate;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
5 tetrabutyrate;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol, tetrabutyrate; and
10 N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate.

Preferred compounds are N-(n-nonyl)-1,5-dideoxy-1,5-
imino-D-glucitol and N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-
glucitol, tetrabutyrate.

15 The N-substituted-imino-D-glucitol compounds useful
in the present invention can be prepared by methods well
known in the art as described in, for example, U.S.
Patents Nos. 4,182,767, 4,639,436, and 5,003,072, as well
as PCT International Publication WO 95/19172 and the
20 references cited therein. Methods for introducing oxygen
into alkyl side chains are disclosed in Tan et al., (1994)
Glycobiology 4(2):141-149. Non-limiting illustrative
preparation procedures are presented below in Examples 1
and 2.

25 In treating hepatitis virus infections, one can use
the anti-hepatitis virus combinations or individual
compounds of this invention in the form of salts derived
from inorganic or organic acids. These salts include but
are not limited to the following: acetate, adipate,
30 alginate, citrate, aspartate, benzoate, benzenesulfonate,
bisulfate, butyrate, camphorate, camphorsulfonate,
digluconate, cyclopentanepropionate, dodecylsulfate,
ethanesulfonate, glucoheptanoate, glycerophosphate,
hemisulfate, heptanoate, hexanoate, fumarate,
35 hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-
ethanesulfonate, lactate, maleate, methanesulfonate,

nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

5 The basic nitrogen-containing groups can be
quaternized with agents such as lower alkyl halides, such
as methyl, ethyl, propyl, and butyl chloride, bromides,
and iodides; dialkyl sulfates such as dimethyl, diethyl,
dibutyl, and diamyl sulfates; long chain halides such as
10 decyl, lauryl, myristyl, and stearyl chlorides, bromides,
and iodides; aralkyl halides such as benzyl and phenethyl
bromides, and others. Water- or oil-soluble or
dispersible products are thereby obtained as desired. The
salts are formed by combining the basic compounds with the
15 desired acid.

Other compounds of the combinations of this invention
that are acids can also form salts. Examples include
salts with alkali metals or alkaline earth metals, such as
sodium, potassium, calcium, or magnesium, or with organic
bases or basic quaternary ammonium salts.
20


Compounds of the combinations of this invention may
be acids or bases. As such, they may be used to form
salts with one another. For example, the phosphoric acid
form of (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate will
25 form a salt with the base form of *N*-(*n*-nonyl)-1,5-dideoxy-
1,5-imino-D-glucitol or *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-
D-glucitol, tetrabutyrate. This type of salt can then be
provided to the patient in a pharmaceutically acceptable
formulation or as a pure single salt.

30 In some cases, the salts can also be used as an aid
in the isolation, purification, or resolution of the
compounds of this invention.

Nucleosides and Nucleotides

35 Nucleosides and nucleotides useful in the present
invention are purine (II) base compounds or pyrimidine

(III) base compounds, or analogs such as compounds IV or V.



Position numbering for purines and pyrimidines is as shown in structures II and III. R¹ can be selected from hydroxyalkyl, hydroxyalkenyl, thiolalkyl, alkylthioalkyl, alkoxyalkyl, alkoxyalkenyl, heterocycle, heterocycloalkyl, hydroxyalkylalkoxyalkyl, alkoxyalkylalkoxyalkyl, and cycloalkylalkyl. The purine compounds can be further substituted at positions 1, 2, 3, 6, 7, or 8 of the purine heterocycle, and the pyrimidine compounds can be substituted at positions 2, 3, 4, 5, or 6 of the pyrimidine heterocycle. Such substituents can be selected from hydroxy, alkoxy, halo, thiol, amino, mono-substituted amino, di-substituted amino, and alkyl.

When used in combination with another radical when referring to the purines and pyrimidines useful in the present invention, the term "alkyl" means a straight or branched chain hydrocarbon radical containing from 1 to 8 carbon atoms, preferably 1 to 4 carbon atoms. When used in combination with another radical, the term "alkenyl" means a straight or branched chain hydrocarbon radical having 1 or more double bonds, containing from 2 to 8 carbon atoms, preferably 1 to 4 carbon atoms. When used alone when referring to purines and pyrimidines useful in the present invention, the term "alkyl" means a straight or branched chain alkyl radical containing from six to 14 carbon atoms, preferably seven to 12 carbon atoms, and most preferably eight to 11 carbon atoms. The term "aryl"

alone or in combination with another radical means a phenyl, naphthyl, or indenyl ring, optionally substituted with one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, or nitro. "Alkanoyl" means branched or straight chain alkanecarbonyl having a chain length of C₁ to C₂₀, preferably C₂ to C₁₄, more preferably C₄ to C₁₀; "aroyl" means arylcarbonyl; and "trifluoroalkanoyl" means alkyl containing three fluoro substituents. "Halogen" means fluorine, chlorine, bromine, or iodine. "Thiol" means sulfur substituted with hydrogen (-SH). "Amino" means nitrogen with two hydrogen atoms; "monosubstituted amino" and "disubstituted amino" mean amino groups further independently substituted with one or more alkyl or arylalkyl groups. "Hydroxyalkyl" means an alkyl group substituted with one or more hydroxyl groups; "hydroxy-alkenyl" means an alkenyl group substituted with one or more hydroxyl groups; "thioalkyl" means an alkyl substituted with one or more thiol (SH) groups; "alkoxyalkyl" means an alkyl substituted with one or more alkyl ether groups; "alkoxyalkenyl" means an alkenyl group substituted with one or more alkyl ether groups; "hydroxyalkylalkoxyalkyl" means an alkoxyalkyl group substituted with a hydroxyalkyl group; "alkoxyalkyl-alkoxyalkyl" means an alkoxyalkyl group substituted with an alkoxyalkyl group; "cycloalkylalkyl" means an alkyl group substituted with a cycloalkyl group. The term "heterocycle," alone or in combination, means a saturated or partially unsaturated 5 or 6-membered ring containing one or more oxygen, nitrogen, and/or sulfur heteroatoms.

Said heterocycle can further be substituted with one to four substituents, which can be independently, hydroxy, hydroxyalkyl, thiol, alkoxy, azido, nitro, a halogen atom, amino, mono-substituted amino, or disubstituted amino. Heterocycloalkyl means an alkyl group wherein one or more hydrogen atoms are replaced by a substituted or unsubstituted heterocyclic ring.

Also included are the tautomers of the substituents on the compounds of the invention. Non-limiting examples of tautomers are ketone/enol tautomers, imino/amino tautomers, *N*-substituted imino/*N*-substituted amino 5 tautomers, thiol/thiacarbonyl tautomers, and ring-chain tautomers such as the five and six membered ring oxygen, nitrogen, sulfur, or oxygen- and sulfur-containing heterocycles also containing substituents alpha to the heteroatoms. Also specifically included in the present 10 invention are enantiomers and diastereomers, as well as racemates and isomeric mixtures of the compounds discussed herein.

Representative nucleoside and nucleotide compounds useful in the present invention include, but are not 15 limited to:

(+)-*cis*-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine;
(-)-2'-deoxy-3'-thiacytidine-5'-triphosphate (3TC);
(-)-*cis*-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine (FTC);
(-)2',3', dideoxy-3'-thiacytidine [(-)-SddC];
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC);
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-20 iodocytosine triphosphate (FIACTP);
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-methyluarcil (FMAU);
1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide;
2',3'-dideoxy-3'-fluoro-5-methyl-dexocytidine (FddMeCyt);
30 2',3'-dideoxy-3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
2',3'-dideoxy-3'-amino-5-methyl-dexocytidine (AddMeCyt);
2',3'-dideoxy-3'-fluoro-5-methyl-cytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-cytidine (ClddMeCyt);
2',3'-dideoxy-3'-amino-5-methyl-cytidine (AddMeCyt);
35 2',3'-dideoxy-3'-fluorothymidine (FddThd);
2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC);

2',3'-dideoxy-beta-L-5-thiacytidine;
2',3'-dideoxy-beta-L-5-cytidine (beta-L-ddC);
2'-deoxy-3'-thia-5-fluorocytosine;
3'-amino-5-methyl-dexocytidine (AddMeCyt);
5 3'-azido-3'-deoxythymidine (AZT);
3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
9-(2-phosphonyl-methoxyethyl)-2',6'-diaminopurine-2',3'-
dideoxyriboside;
9-(2-phosphonylmethoxyethyl)adenine (PMEA);
10 acyclovir triphosphate (ACVTP);
D-carbocyclic-2'-deoxyguanosine (CdG);
dideoxy-cytidine;
dideoxy-cytosine (ddC);
dideoxy-guanine (ddG);
15 dideoxy-inosine (ddI);
E-5-(2-bromovinyl)-2'-deoxyuridine triphosphate;
fluoro-arabinofuranosyl-iodouracil;
stavudine;
2-deoxy-3'-thia-5-fluorocytidine;
20 2',3'-dideoxy-guanine; and
2',3'-dideoxy-guanosine.

A preferred compound is (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC).

Synthetic methods for the preparation of nucleosides
25 and nucleotides useful in the present invention are
likewise well known in the art as disclosed in *Acta
Biochim. Pol.*, **43**, 25-36 (1996); *Swed. Nucleosides
Nucleotides* **15**, 361-378 (1996), *Synthesis* **12**, 1465-1479
(1995), *Carbohyd. Chem.* **27**, 242-276 (1995), *Chem.
30 Nucleosides Nucleotides* **3**, 421-535 (1994), *Ann. Reports in
Med. Chem.*, Academic Press; and *Exp. Opin. Invest. Drugs*
4, 95-115 (1995).

The chemical reactions described in the references
cited above are generally disclosed in terms of their
35 broadest application to the preparation of the compounds
of this invention. Occasionally, the reactions may not be

applicable as described to each compound included within the scope of compounds disclosed herein. The compounds for which this occurs will be readily recognized by those skilled in the art. In all such cases, either the 5 reactions can be successfully performed by conventional modifications known to those skilled in the art, e.g., by appropriate protection of interfering groups, by changing to alternative conventional reagents, by routine modification of reaction conditions, and the like, or 10 other reactions disclosed herein or otherwise conventional will be applicable to the preparation of the corresponding compounds of this invention. In all preparative methods, all starting materials are known or readily preparable from known starting materials.

15 While nucleoside analogs are generally employed as antiviral agents as is, nucleotides (nucleoside phosphates) must sometimes have to be converted to nucleosides in order to facilitate their transport across cell membranes. An example of a chemically modified 20 nucleotide capable of entering cells is S-1-3-hydroxy-2-phosphonylmethoxypropyl cytosine (HPMPC, Gilead Sciences).

Immunomodulators and Immunostimulants

A large number of immunomodulators and immuno- 25 stimulants that can be used in the methods of the present invention are currently available. A list of these compounds is provided in Table 1, below.

TABLE 1

DRUG NAME

| | |
|----|---|
| | AA-2G |
| 5 | adamantylamide dipeptide adenosine deaminase, Enzon adjuvant, Alliance adjuvants, Ribi adjuvants, Vaxcel Adjuvax |
| 10 | agelasphin-11 AIDS therapy, Chiron algal glucan, SRI algammulin, Anutech Anginlyc |
| 15 | anticellular factors, Yeda Anticort |
| 20 | antigastrin-17 immunogen, Ap antigen delivery system, Vac antigen formulation, IDBC antiGnRH immunogen, Aphton Antiherpin |
| 25 | Arbidol Aviron azarole |
| 30 | Bay-q-8939 Bay-r-1005 BCH-1393 Betafectin Biostim BL-001 BL-009 |
| 35 | Broncostat Cantastim CDRI-84-246 cefodizime chemokine inhibitors, ICOS CMV peptides, City of Hope CN-5888 |
| 40 | cytokine-releasing agent, St DHEAS, Paradigm DISC TA-HSV J07B I01A I01Z |

ditiocarb sodium
ECA-10-142
ELS-1
endotoxin, Novartis
5 FCE-20696
FCE-24089
FCE-24578
FLT-3 ligand, Immunex
FR-900483
10 FR-900494
FR-901235
FTS-Zn
G-proteins, Cadus
gludapcin
15 glutaurine
glycophosphopeptical
GM-2
GM-53
GMDP
20 growth factor vaccine, EntreM
H-BIG, NABI
H-CIG, NABI
HAB-439
25 Helicobacter pylori vaccine,
herpes-specific immune factor
HIV therapy, United Biomed
HyperGAM+CF
ImmuMax
Immun BCG
30 immune therapy, Connective
immunomodulator, Evans
immunomodulators, Novacell
imreg-1
imreg-2
35 Indomune
inosine pranobex
interferon, Dong-A (alpha2)
interferon, Genentech (gamma)
interferon, Novartis (alpha)
40 interleukin-12, Genetics Ins
interleukin-15, Immunex
interleukin-16, Research Cor
ISCAR-1
J005X
45 L-644257
licomarasminic acid
LipoTher
LK-409
LK-410
50 LP-2307
LT(R1926)
LW-50020
MAF, Shionogi

22/1

MDP derivatives, Merck
met-enkephalin, TNI
methylfurylbutyrolactones
MIMP

mirimostim
mixed bacterial vaccine, Tem
MM-1
moniliastat
MPLA, Ribi
MS-705
murabutide
murabutide, Vacsyn
muramyl dipeptide derivative
muramyl peptide derivatives
myelopid
N-563
NACOS-6
NH-765
NISV, Proteus
NPT-16416
NT-002
PA-485
PEFA-814
peptides, Scios
peptidoglycan, Pliva
Perthon, Advanced Plant
PGM derivative, Pliva
Pharmaprojects No. 1099
Pharmaprojects No. 1426
Pharmaprojects No. 1549
Pharmaprojects No. 1585
Pharmaprojects No. 1607
Pharmaprojects No. 1710
Pharmaprojects No. 1779
Pharmaprojects No. 2002
Pharmaprojects No. 2060
Pharmaprojects No. 2795
Pharmaprojects No. 3088
Pharmaprojects No. 3111
Pharmaprojects No. 3345
Pharmaprojects No. 3467
Pharmaprojects No. 3668
Pharmaprojects No. 3998
Pharmaprojects No. 3999
Pharmaprojects No. 4089
Pharmaprojects No. 4188
Pharmaprojects No. 4451
Pharmaprojects No. 4500
Pharmaprojects No. 4689
Pharmaprojects No. 4833
Pharmaprojects No. 494
Pharmaprojects No. 5217
Pharmaprojects No. 530
pidotimod
pimelautide
pinafide
PMD-589

23/1

podophyllotoxin, Conpharm
POL-509
poly-ICLC
poly-ICLC, Yamasa Shoyu
PolyA-PolyU
Polysaccharide A

protein A, Berlox Bioscience
PS34WO
pseudomonas MAbs, Teijin
Psomaglobin
5 PTL-78419
Pyrexol
pyriferone
Retrogen
Retropеп
RG-003
Rhinostat
rifamaxil
RM-06
Rollin
10 romurtide
RU-40555
RU-41821
rubella antibodies, ResCo
S-27609
SB-73
SDZ-280-636
SDZ-MRL-953
SK&F-107647
SL04
20 SL05
SM-4333
Solutein
SRI-62-834
SRL-172
ST-570
ST-789
staphage lysate
Stimulon
suppressin
30 T-150R1
T-LCEF
tabilautide
temurtide
Theradigm-HBV
Theradigm-HPV
40 Theradigm-HSV
THF, Pharm & Upjohn
THF, Yeda
thymalfasin
thymic hormone fractions
45 thymocartin
thymolymphotropin
thymopentin
thymopentin analogues
50 thymopentin, Peptech
thymosin fraction 5, Alpha
thymostimulin
thymotrinan

24/1

TMD-232
TO-115
transfer factor, Viragen
tuftsin, Selavo
ubenimex
Ulsastat

ANGG-
CD-4+
Collag+
COLSF+
COM+
DA-A+
GAST-
GF-TH+
GP-120-
IF+
IF-A+
IF-A-2+
IF-B+
IF-G+
IF-G-1B+
IL-2+
IL-12+
IL-15+
IM+
LHRH-
LIPCOR+
LYM-B+
LYM-NK+
LYM-T+
OPI+
PEP+
PHG-MA+
RNA-SYN-
SY-CW-
TH-A-1+
TH-5+
TNF+
UN

Dosages

The *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds useful in the present invention can be administered to humans in an amount in the range of from 5 about 0.1 mg/kg/day to about 100 mg/kg/day, more preferably from about 1 mg/kg/day to about 75 mg/kg/day, and most preferably from about 5 mg/kg/day to about 50 mg/kg/day.

The nucleoside or nucleotide antiviral compound, or mixtures thereof, can be administered to humans in an amount in the range of from about 0.1 mg/person/day to 10 about 500 mg/person/day, preferably from about 10 mg/person/day to about 300 mg/person/day, more preferably from about 25 mg/person/day to about 200 mg/person/day, 15 even more preferably from about 50 mg/person/day to about 150 mg/person/day, and most preferably in the range of from about 1 mg/person/day to about 50 mg/person/day.

Immunomodulators and immunostimulants useful in the present invention can be administered in amounts lower than those conventional in the art. For example, thymosin alpha 1 and thymosin fraction 5 are typically administered to humans for the treatment of HepB infections in an amount of about 900 µg/m², two times per week (*Hepatology* (1988) 8:1270; *Hepatology* (1989) 10:575; *Hepatology* (1991) 14:409; *Gastroenterology* (1995) 108:A1127). In the methods and compositions of the present invention, this dose can be in the range of from about 10 µg/m², two times per week to about 750 µg/m², two times per week, more preferably from about 100 µg/m², two times per week to 20 about 600 µg/m², two times per week, most preferably from about 200 µg/m², two times per week to about 400 µg/m², two times per week. Interferon alfa is typically administered to humans for the treatment of HepC infections in an amount of from about 1 X 10⁶ units/person, three times per week to about 10 X 10⁶ units/person, three times per week 25 (Simon et al., (1997) *Hepatology* 25:445-448). In the 30 35

methods and compositions of the present invention, this dose can be in the range of from about 0.1×10^6 units/person, three times per week to about 7.5×10^6 units/person, three times per week, more preferably from 5 about 0.5×10^6 units/person, three times per week to about 5×10^6 units/person, three times per week, most preferably from about 1×10^6 units/person, three times per week to about 3×10^6 units/person, three times per week.

Due to the enhanced hepatitis virus antiviral 10 effectiveness of these immunomodulators and immunostimulants in the presence of the *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds useful in the present invention, reduced amounts of other 15 immunomodulators/immunostimulants can be employed in the methods and compositions disclosed herein. Such reduced amounts can be determined by routine monitoring of 20 hepatitis virus in infected patients undergoing therapy. This can be carried out by, for example, monitoring hepatitis viral DNA in patients' serum by slot-blot, dot-blot, or PCR techniques, or by measurement of hepatitis surface or other antigens, such as the e antigen, in serum. Methods therefor are discussed in Hoofnagle et al., (1997) *New Engl. Jour. Med.* 336(5):347-356, and F.B. Hollinger in *Fields Virology*, Third Ed., Vol. 2 (1996), 25 Bernard N. Fields et al., Eds., Chapter 86, "Hepatitis B Virus," pp. 2738-2807, Lippincott-Raven, Philadelphia, PA, and the references cited therein.

Patients can be similarly monitored during 30 combination therapy employing *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds and nucleoside and/or nucleotide antiviral agents to determine the lowest effective doses of each.

The doses described above can be administered to a patient in a single dose or in proportionate multiple 35 subdoses. In the latter case, dosage unit compositions can contain such amounts of submultiples thereof to make

up the daily dose. Multiple doses per day can also increase the total daily dose should this be desired by the person prescribing the drug.

Pharmaceutical Compositions

5 The compounds of the present invention can be formulated as pharmaceutical compositions. Such compositions can be administered orally, parenterally, by inhalation spray, rectally, intradermally, transdermally, or topically in dosage unit formulations containing
10 conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein
15 includes subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion techniques.
Formulation of drugs is discussed in, for example, Hoover,
John E., *Remington's Pharmaceutical Sciences*, Mack
Publishing Co., Easton, Pennsylvania (1975), and Liberman,
20 H.A. and Lachman, L., Eds., *Pharmaceutical Dosage Forms*,
Marcel Decker, New York, N.Y. (1980).

25 Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable
30 vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed, including
35 synthetic mono- or diglycerides. In addition, fatty acids

such as oleic acid are useful in the preparation of injectables. Dimethyl acetamide, surfactants including ionic and non-ionic detergents, and polyethylene glycols can be used. Mixtures of solvents and wetting agents such 5 as those discussed above are also useful.

Suppositories for rectal administration of the compounds discussed herein can be prepared by mixing the active agent with a suitable non-irritating excipient such as cocoa butter, synthetic mono-, di-, or triglycerides, 10 fatty acids, or polyethylene glycols which are solid at ordinary temperatures but liquid at the rectal temperature, and which will therefore melt in the rectum and release the drug.

Solid dosage forms for oral administration may 15 include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered *per os*, the compounds can 20 be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, 25 polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets can contain a controlled-release formulation as can be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. In the case of 30 capsules, tablets, and pills, the dosage forms can also comprise buffering agents such as sodium citrate, or magnesium or calcium carbonate or bicarbonate. Tablets and pills can additionally be prepared with enteric coatings.

For therapeutic purposes, formulations for parenteral administration can be in the form of aqueous or non-

aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions can be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the 5 formulations for oral administration. The compounds can be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of 10 administration are well and widely known in the pharmaceutical art.

Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents 15 commonly used in the art, such as water. Such compositions can also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

The amount of active ingredient that can be combined 20 with the carrier materials to produce a single dosage form will vary depending upon the patient and the particular mode of administration.

Certain of the pharmaceutical compounds of this 25 invention which are administered in accordance with the methods of the invention can serve as prodrugs to other compounds of this invention. Prodrugs are drugs that can be chemically converted *in vivo* or *in vitro* by biological systems into an active derivative or derivatives.

Prodrugs are administered in essentially the same fashion 30 as the other pharmaceutical compounds of the invention. Non-limiting examples are the esters of the *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds of this invention.

Treatment Regimen

35 The regimen for treating a patient suffering from a

hepatitis virus infection with the compounds and/or compositions of the present invention is selected in accordance with a variety of factors, including the age, weight, sex, diet, and medical condition of the patient, 5 the severity of the infection, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic, and toxicology profiles of the particular compounds employed, and whether a drug delivery system is utilized.

10 Administration of the drug combinations disclosed herein should generally be continued over a period of several weeks to several months or years until virus titers reach acceptable levels, indicating that infection has been controlled or eradicated. As noted above, 15 patients undergoing treatment with the drug combinations disclosed herein can be routinely monitored by measuring hepatitis viral DNA in patients' serum by slot-blot, dot-blot, or PCR techniques, or by measurement of hepatitis antigens, such as hepatitis B surface antigen (HBsAg) and 20 hepatitis B e antigen (HBeAg), in serum to determine the effectiveness of therapy. In chronic hepatitis B, for example, remissions are characterized by the disappearance of hepatitis B viral DNA, i.e., reduction to undetectable levels as measured by hybridization tests capable of 25 detecting levels $\geq 10^5$ genomes per ml of serum, and HBeAg from serum despite the continued presence of HBsAg. These serologic events are followed by improvement in the biochemical and histologic features of the disease. The end point of successful treatment in most trials of 30 antiviral therapy is the disappearance of HBeAg and viral DNA from serum. In patients in whom the e antigen disappears, remission is usually sustained, and results in an inactive HBsAg carrier state. Many patients eventually become HBsAg-negative (see Hoofnagle et al., 35 (1997) *New Engl. Jour. Med.* 336(5):347-356 for a review). Continuous analysis of the data obtained by these

methods permits modification of the treatment regimen during therapy so that optimal amounts of each component in the combination are administered, and so that the duration of treatment can be determined as well. Thus, 5 the treatment regimen/dosing schedule can be rationally modified over the course of therapy so that the lowest amounts of each of the antiviral compounds used in combination which together exhibit satisfactory anti-hepatitis virus effectiveness are administered, and so 10 that administration of such antiviral compounds in combination is continued only so long as is necessary to successfully treat the infection.

The following non-limiting examples serve to illustrate various aspects of the present invention.

15

Example 1Preparation of1,5-(butylimino)-1,5-dideoxy-D-glucitol

A solution of 1,5-dideoxy-1,5-imino-D-glucitol (5.14 g, 0.0315 mole), butyraldehyde (3.35 ml, 0.0380 20 mole) and Pd black (1 g) in 200 ml methanol was hydrogenated (60 psi/29°C/21 hrs.). After filtering the resulting mixture, the filtrate was concentrated in vacuo to an oil. The title compound was crystallized from acetone, and recrystallized from 25 methanol/acetone, m.p. ca. 132°C. The structure assignment was supported by NMR, infrared spectra and elemental analysis.

Analysis calcd. for C₁₀H₂₁NO₄: C, 54.78; H, 9.65; N, 6.39. Found: C, 54.46; H, 9.33; N, 6.46.

Example 2Preparation of1,5-(butylimino)-1,5-dideoxy-D-glucitol,
tetraacetate

5

Acetic anhydride (1.08 g, 0.0106 mole) was added to the title compound of Example 1 (0.50 g, 0.0023 mole) in 5 ml pyridine and stirred for 17 days at room temperature. The product was evaporated under nitrogen gas. The resulting title compound was purified by silica gel chromatography. Structure assignment was supported by NMR, infrared spectra and elemental analysis.

Analysis calcd. for C₁₈H₂₉NO₉: C, 55.80; H, 7.54; N, 3.62. Found: C, 55.42; H, 7.50; N, 3.72.

Example 3Anti-Hepatitis B Virus Activity of(-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC)Alone and in Combination with N-nonyl-DNJ

20

The anti-hepatitis B virus effect of (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC) alone and in combination with N-nonyl-DNJ was determined according to Korba ((1996) *Antiviral Research* 29(1):49-51), using the "combostat" strategy (Comstat Program, Comstat Corp., Duluth, MN). The combostat method involves serially diluting the IC-90 of each compound. The IC-90 of N-nonyl-DNJ has been determined to be between 4 and 10 µg/ml (T. Block and G. Jacob, unpublished observation). The accepted IC-90 for 3TC in HepG 2.2.15 (2.2.15) cells is 300nM to 500nM (Doong et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:8495-8499).

30

2.2.15 cells, described in Sells et al. (1987) *Proc. Natl. Acad. Sci. USA* 84:1005-1009, were maintained in RPMI 1640 medium (Gibco BRL, #31800-022) supplemented with 10% fetal bovine serum, 200 µg/ml G418 (Gibco BRL 066-1811).

Cells were seeded into 25 cm² flasks at 80% confluency. Five days later, flasks in triplicate received either no compound, serial dilutions of 3TC alone, or serial dilutions of 3TC plus *N*-nonyl-DNJ. At 2, 4, and 6 days 5 after addition of compound (with medium replacement on those days), the amount of hepatitis B virus (HBV) DNA in the culture medium was determined by PCR analysis of polyethyleneglycol-sedimented particles. Thus, in these experiments, enveloped particles were not distinguished 10 from nucleocapsids. PCR-amplified products were resolved by agarose gel electrophoresis (1.5% agarose), and the 538 nucleotide fragment was quantified by band scanning (HP Jet Imager). The amount of HBV recovered from untreated 15 cells is assumed to be 100%. Data from the 6-day time point are presented in Figure 1 as the average values from at least three separate flasks, and the standard error was never greater than 20%, with an average error of 12%.

For each of the three time point series tested, the combination of 3TC plus *N*-nonyl-DNJ was significantly more 20 effective in inhibiting HBV secretion than either compound alone. Conclusions based upon PCR analysis alone make it difficult to assign precise IC-50 values. The extreme sensitivity and delicate nature of PCR, for example, may account for the inability to achieve greater than 90% 25 inhibition of HBV by 3TC alone, even at 300nM. Every experiment included controls to assure that PCR was performed in a range of concentrations of DNA in which the reaction yields results proportional to the amount of DNA 30 in the sample. Resolution is approximately 3-fold, i.e., 3-fold differences in DNA concentrations can be detected. The inability to consistently detect less than 3-fold 35 differences probably explains the failure of 3TC alone to achieve 90% inhibition. This suggests that a very high standard of inhibition must be met for the PCR to detect inhibition. Consequently, the trend, over three separate time points, is clear: the combined effect of 3TC plus

N-nonyl-DNJ is greater than that of either compound alone, or the additive individual effects of each compound. These data suggest that the IC-50 of 3TC has been moved from about 60 nM to about 0.48 nM when 0.016 µg/ml
5 *N-nonyl-DNJ* is present.

Example 4

Anti-Hepatitis B Virus Effect of *N-nonyl-DNJ* Alone
in a Woodchuck Model

In order to evaluate the efficacy of *N-nonyl-DNJ* in
10 combination with 3TC (or other nucleoside or nucleotide
analogs) against Hepatitis B virus in a woodchuck animal
model, an monotherapy experiment using *N-nonyl-DNJ* alone
was first conducted. This was necessary to determine if
15 *N-nonyl-DNJ* has any anti-HBV effect in the woodchuck and,
if *N-nonyl-DNJ* has a beneficial effect, to design a
combination study based on the dose-response relationship
of this drug alone.

Therefore, five groups of four animals each (all
groups had both sexes, all but the control had two of each
20 sex) were assigned to 0, 12.5, 25, 50, and 100 mg/kg/day
with BID oral dosing. These were lab-reared wild animals.
All animals were infected with woodchuck hepatitis virus
(WHV) as neonates, and had been tested positive on
serological tests for WHV surface antigen. Blood samples
25 were drawn one week prior to dosing (-1 week), immediately
before dosing (0 weeks), weekly during dosing (1, 2, 3,
and 4 weeks), and after the end of dosing (5, 6, 8, and 10
weeks).

There are two measures of drug efficacy: reduction in
30 total HBV DNA (measured by quantitative PCR), and
reduction in HBV DNA from capsids with intact surface
glycoproteins, which is the active form of the virus
(measured by an ELISA-like immune precipitation assay
followed by quantitative PCR). Cell culture experiments
35 with *N-nonyl-DNJ* demonstrated little or no effect of this

compound on total HBV DNA, but a marked effect on the immune precipitated DNA (IPDNA). Not surprisingly, the IPDNA assay is quite variable; as a partial compensation for this, four assay runs were conducted, each containing 5 samples from all animals, but different subsets of the study weeks.

To summarize the results, *N*-nonyl-DNJ had no effect on total HBV DNA measurements, which were essentially constant for all dose levels over the pre-dose and dosed 10 portions of the study. On the other hand, IPDNA levels were not constant over the study period. The low dose animals tended to have increasing levels of IPDNA over the dosing period (weeks 0-4), while high dose animals tended to have decreasing levels of IPDNA over the same period. 15 Fitting a straight line to each animal's weekly responses gave a significant difference in the slope of these lines due to either dose or plasma level of drug. The plasma levels of drug were also quite variable: animals with the lowest plasma levels in their dose group had lower plasma 20 levels than the animals with the highest plasma levels from the next lower dose group. There were no differences between responses of males and females on any of the measures.

Plasma Levels

25 There were no clear patterns in the changes in plasma levels of *N*-nonyl-DNJ which could be related to week of dosing or time since previous dose. Because the plasma levels within an animal seemed reasonably consistent during dosing, the median plasma level for each animal was 30 used for subsequent modeling. The plasma levels for each week of the dosing period are plotted for each animal vs. dose (a small amount of random noise is added to the dose level so points which would lie on top of each other on the plot can be distinguished) (Figure 2).

HBV DNA

The total HBV DNA levels were essentially constant over time within each animal (data not shown). There was a faint hint of a dose-response relationship with
5 decreasing levels of virus with increasing levels of drug, except that three animals at the highest dose had very high virus levels. It is not possible to conclude that there is any relationship between dose of *N*-nonyl-DNJ and total HBV DNA. It is possible that there are two
10 populations of animals, responders (such as animal r) and non-responders (animals i, m, and d), but more data would be required to permit a firm conclusion on this point.

Immune Precipitated HBV DNA

Substantial variation existed in the IPDNA assay,
15 both between assay runs and within assay runs (data not shown). Even so, it was possible to observe and model a slope over weeks 0-4 which is generally increasing for low dose animals and decreasing for high dose animals. This change in slope was statistically significant ($p<0.005$).

Before models are fitted to the data, a log transform
20 was applied because: 1) the variation in IPDNA increases with increasing IPDNA values; the log transformation gives values with a nearly constant variation, and 2) it is expected that drug effects will appear as a constant
25 multiplier of the IPDNA level. Because there are zero values of IPDNA, a small value (about 1/2 of the smallest non-zero value) was added to all values before the log transform.

Two approaches were used to model the changes in
30 slope to week with dose of *N*-nonyl-DNJ: a linear modeling approach and a nonlinear model. Both approaches assume that the (linear) rate of change of the Log(IPDNA) measure over the dosing period is the "right" measure to reflect the effect of the drug on the virus. Both approaches are fit in stages, and the first stage is common to both
35

approaches. First, a simple straight line regression model is fit using weeks 0-4 to predict $\log(\text{IPDNA} + 10)$ separately for each animal by run combination. In the second stage, the response variable is the slope fitted in 5 the first stage.

For the linear approach, a model is fit with slope to week as the response where run is considered a block, dose has a significant effect (almost all of this effect is due to a slope to dose), and the relevant error for testing 10 the effect of dose is the variation among animals treated alike (after the adjustment for the runs as blocks). This is similar to using the calibration data within each run to first adjust each run's data to a common virus DNA concentration; the difference is that here the data from 15 the woodchucks are used for the run adjustment rather than only the calibration data.

For the nonlinear approach, a four parameter logistic model is fit with the slope to week as the response and the dose as the predictor. Again, run is considered a 20 block, but because no run has all weeks, it is not possible to fully reflect the blocking in the nonlinear approach. Even so, the nonlinear model yields an EC50 of 7.88 mg/kg/BID dose. The average maximum slope observed was 2.71 additional $\log(\text{IPDNA } \mu\text{g/mL})/\text{week}$, or an increase 25 of about 150%/week, the average minimum slope observed with *N*-nonyl-DNJ is 0.31 fewer $\log(\text{IPDNA } \mu\text{g/mL})/\text{week}$, or about a decrease of about 25%/week. The slopes, the fitted model, the parameter estimates from the model, and the approximate standard errors for these parameters are 30 all shown in Figure 3. The data indicate an approximate effective monotherapy dose of *N*-nonyl-DNJ in woodchucks of about 16 mg/kg/day. Whether in woodchucks or humans, the effective dose of both the *N*-alkyl-DNJ and nucleoside or nucleotide antiviral agent 35 administered in combination therewith can be administered in two equal daily subdoses (i.e., B.I.D.).

Figures 2 and 3 show letters to indicate animals. Table 2 shows two of the animal codes, the sex, and the dose.

TABLE 25 Animal Codes, Sex, and Dose

| | <u>Animal Number</u> | <u>Letter Code</u> | <u>Sex</u> | <u>Dose</u> |
|----|----------------------|--------------------|------------|-------------|
| | F95343 | b | F | 0 |
| | M96364 | n | M | 0 |
| | F96304 | k | F | 0 |
| 10 | F96301 | j | F | 0 |
| | M96285 | h | M | 6.25 |
| | F96283 | g | F | 6.25 |
| | F96391 | o | F | 6.25 |
| | M96305 | l | M | 6.25 |
| 15 | F96271 | f | F | 12.5 |
| | M96256 | e | M | 12.5 |
| | M96404 | s | M | 12.5 |
| | F96392 | p | F | 12.5 |
| | F96163 | c | F | 25 |
| 20 | M96414 | t | M | 25 |
| | F96393 | q | F | 25 |
| | M95322 | a | M | 25 |
| | M96286 | i | M | 50 |
| | F96231 | d | F | 50 |
| 25 | F96402 | r | F | 50 |
| | M96363 | m | M | 50 |

Example 5Antiviral Study to Test the Activity of
N-nonyl-DNJ in Combination with 3TCin a Woodchuck Model of Hepatitis B Virus Infection

5 The combined activity of N-nonyl-DNJ and the nucleoside analog 3TC can be assessed using the woodchuck model of hepatitis B virus infection. Twenty-eight woodchucks with persistent woodchuck hepatitis virus (WHV) infection can be utilized. Groups of woodchucks can be 10 treated orally with 3TC alone (s.i.d.), with N-nonyl-DNJ alone (b.i.d.), or with combinations of the two drugs. The antiviral activity of the individual drugs and combinations can be assessed by measuring serum WHV DNA during treatment, and comparing the results of treated 15 groups to placebo treated controls.

Twenty-eight woodchucks with established persistent WHV infection can be used, all of which were experimentally infected with WHV during the first week of life. All can be WHsAg positive at the time the study is 20 initiated.

A total of eight experimental groups can be used. Woodchucks in each group can be stratified on the basis of gender, body weight, and age. 3TC can be administered orally as an aqueous suspension of Epivir (Glaxo-Wellcome) 25 tablets one time per day. N-nonyl-DNJ can also be administered orally in aqueous solution, in two divided doses. Treatment with both drugs can be followed by the administration of 4 to 5 mls of semisynthetic liquid woodchuck diet to insure complete ingestion of the drugs.

30 The experimental groups can be as follows:

| Group | No. | 3TC (mg/kg/day) | N-nonyl-DNJ (mg/kg/day) |
|-------|-----|--------------------|----------------------------|
| ID | | | |
| 1 | 4 | 0.0 | 0.0 |
| 2 | 3 | 3.0 | 0.0 |
| 5 | 3 | 9.0 | 0.0 |
| 4 | 3 | 0.0 | 4.0 |
| 5 | 3 | 0.0 | 12.0 |
| 6 | 4 | 1.5 | 2.0 |
| 7 | 4 | 4.5 | 6.0 |
| 10 | 8 | 4 | 9.0 |
| | | | 12.0 |


Woodchucks can be anesthetized (50mg/kg ketamine, 5mg/kg zylazine), weighed, and blood samples obtained prior to initial treatment, at weekly intervals during the six week period of treatment, and at 1, 2, and 4 weeks following treatment. Serum can be harvested and divided into aliquots. One aliquot can be used for analysis of WHV DNA by dot blot hybridization and for WHsAg by ELISA. CBCs and clinical biochemical profiles can be obtained prior to treatment and at the end of treatment. A second aliquot can be maintained as an archive sample. Other aliquots of serum can be used for drug analysis and special WHV DNA analyses.

The invention being thus described, it will be obvious that the same can be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the present invention, and all such

modifications and equivalents as would be obvious to one skilled in the art are intended to be included within the scope of the following claims.

What Is Claimed Is:

1. A method of treating a hepatitis virus infection in a mammal, comprising administering to said mammal a first amount of an N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



I

wherein:

10 R is selected from the group consisting of arylalkyl, cycloalkylalkyl, and branched or straight chain alkyl having a chain length of C₁ to C₂₀, and

15 W, X, Y, and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

a second amount of an antiviral compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral compound, and mixtures thereof,

20 wherein said first and second amounts of said compounds together comprise an anti-hepatitis virus effective amount of said compounds.

2. The method of claim 1, wherein R is a branched or straight chain alkyl having a chain length of C₁ to C₂₀, and W, X, Y, and Z are each hydrogen.

3. The method of claim 2, wherein R is a straight chain alkyl having a chain length of C₁ to C₂₀.

4. The method of claim 3, wherein R is a straight chain alkyl having a chain length of C₂ to C₁₄.

5. The method of claim 4, wherein R is a straight chain alkyl having a chain length of C₆ to C₁₂.

6. The method of claim 5, wherein R is nonyl.

7. The method of claim 1, wherein R is a branched or straight chain alkyl having a chain length of C₁ to C₂₀, and W, X, Y, and Z are each alkanoyl.

8. The method of claim 7, wherein R is a straight chain alkyl having a chain length of C₁ to C₂₀.

9. The method of claim 8, wherein R is a straight chain alkyl having a chain length of C₂ to C₁₄.

10. The method of claim 9, wherein R is a straight chain alkyl having a chain length of C₆ to C₁₂.

11. The method of claim 10, wherein R is nonyl.

12. The method of claim 7, wherein said alkanoyl has a chain length of C₁ to C₂₀.

13. The method of claim 7, wherein said alkanoyl has a chain length of C₂ to C₁₄.

14. The method of claim 7, wherein said alkanoyl has a chain length of C₃ to C₁₀.

15. The method of claim 7, wherein said alkanoyl is butanoyl.

16. The method of claim 7, wherein R is nonyl and W, X, Y, and Z are each butanoyl.

17. The method of claim 1, wherein
R is a straight chain alkyl having a chain length of C₁ to C₂₀,

W, X, Y, and Z are each hydrogen, and
5 said antiviral compound is a nucleoside antiviral compound.

18. The method of claim 1, wherein
R is a straight chain alkyl having a chain length of C₁ to C₂₀,

W, X, Y, and Z are each butanoyl, and
5 said antiviral compound is a nucleoside antiviral compound.

19. The method of claim 1, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-hexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
5 N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
10 tetrabutyrate;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
15 N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N- (n-undecyl-) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (n-dodecyl-) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (2-ethylhexyl) -1,5-dideoxy-1,5-imino-D-glucitol;
20 N- (4-ethylhexyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (5-methylhexyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (3-propylhexyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (1-pentylpentylhexyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (1-butylbutyl) -1,5-dideoxy-1,5-imino-D-glucitol;
25 N- (7-methyloctyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (8-methylnonyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (9-methyldecyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (10-methylundecyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (6-cyclohexylhexyl) -1,5-dideoxy-1,5-imino-D-glucitol;
30 N- (4-cyclohexylbutyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (2-cyclohexylethyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (1-cyclohexylmethyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (1-phenylmethyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (3-phenylpropyl) -1,5-dideoxy-1,5-imino-D-glucitol;
35 N- (3-(4-methyl)-phenylpropyl) -1,5-dideoxy-1,5-imino-D-
glucitol;
N- (6-phenylhexyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (n-nonyl-) -1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
40 N- (n-decyl-) -1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N- (n-undecyl-) -1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N- (n-dodecyl-) -1,5-dideoxy-1,5-imino-D-glucitol,
45 tetrabutyrate;
N- (2-ethylhexyl) -1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N- (4-ethylhexyl) -1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
50 N- (5-methylhexyl) -1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N- (3-propylhexyl) -1,5-dideoxy-1,5-imino-D-glucitol,

tetrabutyrate;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
55 tetrabutyrate;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
60 N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
65 tetrabutyrate;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
70 N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
75 tetrabutyrate;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol, tetrabutyrate; and
80 N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate, and
said nucleoside or nucleotide antiviral compound is
selected from the group consisting of:
(+)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-
85 yl]cytosine;
(-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC);
(-)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-
yl]cytosine (FTC);

(-)2',3', dideoxy-3'-thiacytidine [(-)-SddC];
90 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-
iodocytosine (FIAC);
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-
iodocytosine triphosphate (FIACTP);
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-
95 methyluarcil (FMAU);
1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide;
2',3'-dideoxy-3'-fluoro-5-methyl-dexocytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
2',3'-dideoxy-3'-amino-5-methyl-dexocytidine (AddMeCyt);
100 2',3'-dideoxy-3'-fluoro-5-methyl-cytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-cytidine (ClddMeCyt);
2',3'-dideoxy-3'-amino-5-methyl-cytidine (AddMeCyt);
2',3'-dideoxy-3'-fluorothymidine (FddThd);
2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC);
105 2',3'-dideoxy-beta-L-5-thiacytidine;
2',3'-dideoxy-beta-L-5-cytidine (beta-L-ddC);
2'-deoxy-3'-thia-5-fluorocytosine;
3'-amino-5-methyl-dexocytidine (AddMeCyt);
3'-azido-3'-deoxythymidine (AZT);
110 3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
9-(2-phosphonylmethoxyethyl)-2',6'-diaminopurine-2',3'-
dideoxyriboside;
9-(2-phosphonylmethoxyethyl)adenine (PMEA);
acyclovir triphosphate (ACVTP);
115 D-carbocyclic-2'-deoxyguanosine (CdG);
dideoxy-cytidine;
dideoxy-cytosine (ddC);
dideoxy-guanine (ddG);
dideoxy-inosine (ddI);
120 E-5-(2-bromovinyl)-2'-deoxyuridine triphosphate;
fluoro-arabinofuranosyl-iodouracil;
stavudine;
2-deoxy-3'-thia-5-fluorocytidine;
2',3'-dideoxy-guanine; and

125 2',3'-dideoxy-guanosine.

20. The method of claim 1, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol and *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate, and said nucleoside antiviral compound is (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC).

21. The method of claim 20, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol and said nucleoside antiviral compound is (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC).

22. The method of claim 1, wherein said first amount of said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is in the range of from about 0.1 mg/kg/day to about 100 mg/kg/day.

23. The method of claim 22, wherein said first amount of said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is in the range of from about 1 mg/kg/day to about 75 mg/kg/day.

24. The method of claim 23, wherein said first amount of said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is in the range of from about 5 mg/kg/day to about 50 mg/kg/day.

25. The method of claim 1, wherein said second amount of said nucleoside or nucleotide antiviral compound, or mixture thereof, is in the range of from about 0.1 mg/person/day to about 500 mg/person/day.

26. The method of claim 25, wherein said second amount of said nucleoside or nucleotide antiviral compound, or mixture thereof, is in the range of from about 10 mg/person/day to about 300 mg/person/day.

27. The method of claim 26, wherein said second amount of said nucleoside or nucleotide antiviral compound, or mixture thereof, is in the range of from about 25 mg/person/day to about 200 mg/person/day.


28. The method of claim 27, wherein said second amount of said nucleoside or nucleotide antiviral compound, or mixture thereof, is in the range of from about 50 mg/person/day to about 150 mg/person/day.

29. The method of claim 1, wherein said second amount of said nucleoside or nucleotide antiviral compound, or mixture thereof, is in the range of from about 1 mg/person/day to about 50 mg/person/day.

30. The method of claim 1, wherein said hepatitis virus infection is a hepatitis B virus infection.

31. A method of treating a hepatitis B virus infection in a mammal, comprising administering to said mammal from about 0.1 mg/kg/day to about 100 mg/kg/day of an N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound
5 of Formula I:

51



I

wherein:

R is selected from the group consisting of arylalkyl,
10 cycloalkylalkyl, and branched or straight chain alkyl
having a chain length of C₁ to C₂₀, and

W, X, Y, and Z are each independently selected from
the group consisting of hydrogen, alkanoyl, aroyl, and
trifluoroalkanoyl; and

15 from about 0.1 mg/person/day to about 500
mg/person/day of a compound selected from the group
consisting of a nucleoside antiviral compound, a
nucleotide antiviral, and mixtures thereof.


32. The method of claim 31, wherein said
N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is
selected from the group consisting of N-(n-nonyl)-1,5-
dideoxy-1,5-imino-D-glucitol and N-(n-nonyl)-1,5-dideoxy-
5 1,5-imino-D-glucitol, tetrabutyrate, and said nucleoside
antiviral agent is (-)-2'-deoxy-3'-thiocytidine-5'-
triphosphate (3TC).

33. The method of claim 32, wherein said
N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol.

34. A method of treating a hepatitis B virus
infection in a human patient, comprising administering to
said human patient from about 0.1 mg/kg/day to about 100

mg/kg/day of *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol
 5 and from about 0.1 mg/person/day to about 500
 mg/person/day of (-)-2'-deoxy-3'-thiocytidine-5'-
 triphosphate.

35. A composition, comprising an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I:



I

5 wherein:

R is selected from the group consisting of arylalkyl, cycloalkylalkyl, and branched or straight chain alkyl having a chain length of C₁ to C₂₀, and

10 W, X, Y, and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

an antiviral compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral compound, and mixtures thereof.

36. A pharmaceutical composition, comprising a first amount of an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I:

wherein:

5 R is selected from the group consisting of arylalkyl, cycloalkylalkyl, and branched or straight chain alkyl having a chain length of C₁ to C₂₀, and

W, X, Y, and Z are each independently selected from

the group consisting of hydrogen, alkanoyl, aroyl, and
10 trifluoroalkanoyl; and

a second amount of an antiviral compound selected
from the group consisting of a nucleoside antiviral
compound, a nucleotide antiviral compound, and mixtures
thereof, and

15 a pharmaceutically acceptable carrier, diluent, or
excipient.

37. The pharmaceutical composition of claim 36,
wherein said first and second amounts of said
compounds together comprise an anti-hepatitis virus
effective amount of said compounds.

38. The pharmaceutical composition of claim 36,
wherein R is a branched or straight chain alkyl having a
chain length of C₁ to C₂₀, and W, X, Y, and Z are each
hydrogen.

39. The pharmaceutical composition of claim 38,
wherein R is a straight chain alkyl having a chain length
of C₁ to C₂₀.

40. The pharmaceutical composition of claim 39,
wherein R is a straight chain alkyl having a chain length
of C₂ to C₁₄.

41. The pharmaceutical composition of claim 40,
wherein R is a straight chain alkyl having a chain length
of C₆ to C₁₂.

42. The pharmaceutical composition of claim 41,
wherein R is nonyl.

43. The pharmaceutical composition of claim 36,
wherein R is a branched or straight chain alkyl having a

chain length of C₁ to C₂₀, and W, X, Y, and Z are each alkanoyl.

44. The pharmaceutical composition of claim 43, wherein R is a straight chain alkyl having a chain length of C₁ to C₂₀.

45. The pharmaceutical composition of claim 44, wherein R is a straight chain alkyl having a chain length of C₂ to C₁₄.

46. The pharmaceutical composition of claim 45, wherein R is a straight chain alkyl having a chain length of C₆ to C₁₂.

47. The pharmaceutical composition of claim 46, wherein R is nonyl.

48. The pharmaceutical composition of claim 43, wherein said alkanoyl has a chain length of C₁ to C₂₀.

49. The pharmaceutical composition of claim 43, wherein said alkanoyl has a chain length of C₂ to C₁₄.

50. The pharmaceutical composition of claim 43, wherein said alkanoyl has a chain length of C₃ to C₁₀.

51. The pharmaceutical composition of claim 43, wherein said alkanoyl is butanoyl.

52. The pharmaceutical composition of claim 43, wherein R is nonyl and W, X, Y, and Z are each butanoyl.

53. The pharmaceutical composition of claim 36, wherein

R is a straight chain alkyl having a chain length of C₁ to C₂₀,

5 W, X, Y, and Z are each hydrogen, and

said antiviral compound is a nucleoside antiviral compound.

54. The pharmaceutical composition of claim 36, wherein

R is a straight chain alkyl having a chain length of C₁ to C₂₀,

5 W, X, Y, and Z are each butanoyl, and

said antiviral compound is a nucleoside antiviral compound.

55. The pharmaceutical composition of claim 36, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

5 N-(n-hexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

10 N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

15 N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N- (n-undecyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (n-dodecyl) -1,5-dideoxy-1,5-imino-D-glucitol;
20 *N*- (2-ethylhexyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (4-ethylhexyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (5-methylhexyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (3-propylhexyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (1-pentylpentylhexyl) -1,5-dideoxy-1,5-imino-D-glucitol;
25 *N*- (1-butylbutyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (7-methyloctyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (8-methylnonyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (9-methyldecyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (10-methylundecyl) -1,5-dideoxy-1,5-imino-D-glucitol;
30 *N*- (6-cyclohexylhexyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (4-cyclohexylbutyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (2-cyclohexylethyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (1-cyclohexylmethyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (1-phenylmethyl) -1,5-dideoxy-1,5-imino-D-glucitol;
35 *N*- (3-phenylpropyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (3-(4-methyl)-phenylpropyl) -1,5-dideoxy-1,5-imino-D-
glucitol;
N- (6-phenylhexyl) -1,5-dideoxy-1,5-imino-D-glucitol;
N- (n-nonyl) -1,5-dideoxy-1,5-imino-D-glucitol,
40 tetrabutyrate;
N- (n-decyl) -1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N- (n-undecyl) -1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
45 *N*- (n-dodecyl) -1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N- (2-ethylhexyl) -1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N- (4-ethylhexyl) -1,5-dideoxy-1,5-imino-D-glucitol,
50 tetrabutyrate;
N- (5-methylhexyl) -1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N- (3-propylhexyl) -1,5-dideoxy-1,5-imino-D-glucitol,

tetrabutyrate;

55 *N*-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol,
60 tetrabutyrate;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

65 *N*-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
70 tetrabutyrate;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

75 *N*-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
80 glucitol, tetrabutyrate; and

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate, and

 said nucleoside or nucleotide antiviral compound is
selected from the group consisting of:

85 (+)-*cis*-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-
yl]cytosine;

 (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC);

 (-)-*cis*-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-
yl]cytosine (FTC);

90 (-) 2',3', dideoxy-3'-thiacytidine [(-)-SddC];
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-
iodocytosine (FIAC);
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-
iodocytosine triphosphate (FIACTP);
95 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-
methyluarcil (FMAU);
1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide;
2',3'-dideoxy-3'-fluoro-5-methyl-dexocytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
100 2',3'-dideoxy-3'-amino-5-methyl-dexocytidine (AddMeCyt);
2',3'-dideoxy-3'-fluoro-5-methyl-cytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-cytidine (ClddMeCyt);
2',3'-dideoxy-3'-amino-5-methyl-cytidine (AddMeCyt);
2',3'-dideoxy-3'-fluorothymidine (FddThd);
105 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC);
2',3'-dideoxy-beta-L-5-thiacytidine;
2',3'-dideoxy-beta-L-5-cytidine (beta-L-ddC);
2'-deoxy-3'-thia-5-fluorocytosine;
3'-amino-5-methyl-dexocytidine (AddMeCyt);
110 3'-azido-3'-deoxythymidine (AZT);
3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
9-(2-phosphonyl-methoxyethyl)-2',6'-diaminopurine-2',3'-
dideoxyriboside;
9-(2-phosphonylmethoxyethyl)adenine (PMEA);
115 acyclovir triphosphate (ACVTP);
D-carbocyclic-2'-deoxyguanosine (CdG);
dideoxy-cytidine;
dideoxy-cytosine (ddC);
dideoxy-guanine (ddG);
120 dideoxy-inosine (ddI);
E-5-(2-bromovinyl)-2'-deoxyuridine triphosphate;
fluoro-arabinofuranosyl-iodouracil;
stavudine;
2-deoxy-3'-thia-5-fluorocytidine;
125 2',3'-dideoxy-guanine; and

2',3'-dideoxy-guanosine.

56. The pharmaceutical composition of claim 36, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol and *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate, and said nucleoside antiviral compound is (-)-2'-deoxy-3'-thiacytidine-5'-triphosphate (3TC).

57. The pharmaceutical composition of claim 56, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol.

58. The pharmaceutical composition of claim 36, wherein said first amount of said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is in the range of from about 0.1 mg to about 100 mg.

59. The pharmaceutical composition of claim 58, wherein said first amount of said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is in the range of from about 1 mg to about 75 mg.

60. The pharmaceutical composition of claim 59, wherein said first amount of said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is in the range of from about 5 mg to about 50 mg.

61. The pharmaceutical composition of claim 36, wherein said second amount of said nucleoside or nucleotide antiviral compound, or mixture thereof, is in the range of from about 0.1 mg to about 500 mg.

60


62. The pharmaceutical composition of claim 61, wherein said second amount of said nucleoside or nucleotide antiviral compound, or mixture thereof, is in the range of from about 10 mg to about 300 mg.

63. The pharmaceutical composition of claim 62, wherein said second amount of said nucleoside or nucleotide antiviral compound, or mixture thereof, is in the range of from about 25 mg to about 200 mg.

64. The pharmaceutical composition of claim 63, wherein said second amount of said nucleoside or nucleotide antiviral compound, or mixture thereof, is in the range of from about 50 mg to about 150 mg.

65. The pharmaceutical composition of claim 36, wherein said second amount of said nucleoside or nucleotide antiviral compound, or mixture thereof, is in the range of from about 1 mg to about 50 mg.

66. A pharmaceutical composition for treating a hepatitis B virus infection in a mammal, comprising from about 0.1 mg to about 100 mg of an N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I:



5

I

wherein:

R is selected from the group consisting of arylalkyl, cycloalkylalkyl, and branched or straight chain alkyl
10 having a chain length of C₁ to C₂₀, and

W, X, Y, and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

from about 0.1 mg to about 500 mg of a compound
15 selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral, and mixtures thereof.

67. The pharmaceutical composition of claim 66, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol and N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate,
5 and said nucleoside antiviral agent is (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate.

68. The pharmaceutical composition of claim 67, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol.

69. A pharmaceutical composition for treating a hepatitis B virus infection in a human patient, comprising from about 0.1 mg to about 100 mg of N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol and from about 0.1 mg to
5 about 500 mg of (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate.

1/3

FIG.1






FIG.2



3/3

FIG.3



INTERNATIONAL SEARCH REPORT

Internal Application No

PCT/US 98/03004

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/70 // (A61K31/70, 31:445)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ^a | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------------------|--|-----------------------|
| Y | WO 95 06061 A (SEARLE & CO ;MONSANTO CO (US); CHANG MIN S (US); STOLZENBACH JAMES) 2 March 1995 see claim 16 --- | 1-69 |
| Y | BLOCK T M ET AL: "The secretion of human hepatitis B virus if inhibited by the imino sugar, N-butyl-deoxynojirimycin" ANTIVIRAL RESEARCH, 23 (SUPPL. 1). 1994. 79., XP002067579 see the whole document --- - / -- | 1-69 |

Further documents are listed in the continuation of box C.

Patent family members are listed in annex

* Special categories of cited documents .

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

10 June 1998

Date of mailing of the international search report

01.07.1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax. (+31-70) 340-3015

Authorized officer

Leherte, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/03004

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|---|-----------------------|
| Y | DOONG, SHIN LIAN ET AL: "Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogs" PROC. NATL. ACAD. SCI. U. S. A., 1991, 88, 8495-9, XP002067580 see abstract ---- | 1-69 |
| Y | GANEM, BRUCE: "N-Butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin" CHEMTRACTS: ORG. CHEM., 1994, 7, 106-7, XP002067581 see the whole document ----- | 1-69 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 98/03004

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 1-19 22 25-33 35-55 61-66 because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims, it is covered by claims Nos.

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 98/03004

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Although claim(s) 1-34 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Claims Nos.: 1-19 22 25-33 35-55 61-66

In view of the very large number of compounds which are defined by the wording of the claims, the search has been performed on the general idea and the combinations explicitly mentionned in the exemples

INTERNATIONAL SEARCH REPORT

...information on patent family members

Internat...l Application No

PCT/US 98/03004

| Patent document cited in search report | Publication date | Patent family member(s) | | Publication date |
|--|------------------|-------------------------|---|------------------|
| WO 9506061 | A 02-03-1995 | US 5750648 | A | 12-05-1998 |

| | | |
|------------|---|------------|
| AU 7518694 | A | 21-03-1995 |
| ZA 9406325 | A | 21-08-1995 |